Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Fineline Cube Jan 15, 2026
Company Deals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Fineline Cube Jan 15, 2026
Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Fineline Cube Jan 15, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Medical Device

Thermo Fisher’s Oncomine Dx Target Test Gets FDA Green Light as Companion Diagnostic for Servier’s Voranigo

Fineline Cube Oct 22, 2024

US pharmaceutical and biotechnology company Thermo Fisher Scientific (NYSE: TMO) has received marketing approval from...

Company Deals

GSK and Cambridge University Forge £50 Million Partnership to Tackle Immune Diseases

Fineline Cube Oct 22, 2024

UK pharmaceutical giant GSK plc (LON: GSK, NYSE: GSK) has unveiled a significant five-year partnership...

Company Drug

AstraZeneca’s Saphnelo Approved for Use in Guangdong Under ‘Hong Kong-Macau Drug Access’ Policy

Fineline Cube Oct 22, 2024

AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced that its drug Saphnelo...

Company Deals

InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal

Fineline Cube Oct 22, 2024

InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement...

Company Drug

BeiGene’s Tevimbra Receives CHMP Recommendation for Expanded Use in G/GEJ and ESCC Cancers in EU

Fineline Cube Oct 22, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading China-based biotechnology company, has received...

Company Drug

Olymvax Bio Receives NMPA Approval for Clinical Study of Trivalent Influenza Vaccine

Fineline Cube Oct 22, 2024

Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, has announced that...

Drug Medical Device Policy / Regulatory

Guangzhou Releases First Batch of Innovative Drugs and Medical Devices List, Featuring Local Companies

Fineline Cube Oct 22, 2024

The Guangzhou Municipal Industry and Information Technology Bureau has unveiled the first batch of innovative...

Company Drug

Sino Biopharmaceutical’s Anlotinib Receives Ninth Indication Approval from China’s CDE for Soft-Tissue Sarcoma

Fineline Cube Oct 22, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company in China, has announced that it...

Company

GenScript Dissolves Merger with CAR-T Specialist Legend Biotech, Reclassifies as Associated Company

Fineline Cube Oct 22, 2024

GenScript Biotech Corporation (HKG: 1548), a comprehensive life science research and application service and product...

Policy / Regulatory

China’s NMPA Greenlights Pilot Plan for Phased Manufacturing of Biological Products

Fineline Cube Oct 22, 2024

The National Medical Products Administration (NMPA) has given its stamp of approval to the “Pilot...

Company Deals

Otsuka Holdings Weighs Sale of Stake in Medical Device Maker MicroPort Scientific

Fineline Cube Oct 22, 2024

Otsuka Holdings Co., a Japanese pharmaceutical and healthcare company, is reportedly considering the sale of...

Company Deals Medical Device

Dongcheng Pharma Moves to Enhance Portfolio with Acquisition of Rongcheng Medical’s GSA Injection

Fineline Cube Oct 22, 2024

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its intention to acquire...

Company Drug

Johnson & Johnson’s Akeega Approved in China as First Dual Action Tablet for mCRPC

Fineline Cube Oct 21, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading US pharmaceutical company, has announced that China’s...

Company Drug

Everest Medicines’ Nefecon Approved in Taiwan for Primary IgAN Treatment

Fineline Cube Oct 21, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received market...

Company Drug

BeiGene’s Tevimbra Approved in China for NSCLC Patients as Neoadjuvant and Adjuvant Therapy

Fineline Cube Oct 21, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading China-based biotechnology company, has announced...

Policy / Regulatory

Tianjin Municipality Unveils Plan to Boost Synthetic Biology and Biomanufacturing Innovation

Fineline Cube Oct 21, 2024

The People’s Government of Tianjin Municipality has unveiled two significant implementation plans to bolster the...

Company Drug

Novo Nordisk’s Alhemo Receives CHMP Recommendation for Haemophilia Prophylaxis in Europe

Fineline Cube Oct 21, 2024

Novo Nordisk (NYSE: NVO), a Danish pharmaceutical company, has been notified that the Committee for...

Company Deals

Stem-Cell Startup Xellsmart Secures Over RMB 100 Million in Series B1 Financing for Neurological Therapies

Fineline Cube Oct 21, 2024

Xellsmart, a stem-cell startup headquartered in Suzhou, has reportedly secured over RMB 100 million (USD...

Company Drug

Novartis’s Kisqali Receives Positive CHMP Opinion for Early Breast Cancer Treatment in the EU

Fineline Cube Oct 21, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced that the Committee for Medicinal Products...

Company Drug

Kanghong Pharmaceutical’s NASH Drug KH629 Approved for Clinical Trials in China

Fineline Cube Oct 21, 2024

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...

Posts pagination

1 … 224 225 226 … 609

Recent updates

  • Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
  • Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
  • QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
  • Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific
  • WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Company Digital

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins

Company Deals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.